Skip to main content
OpenTrials
Completed

NCT Number: NCT05505890

Effects of Postoperative Analgesic Modalities on Plasma Creatine Phosphokinase(CPK) Levels After Knee Artroplasty

Regional anesthesia and analgesia technics are widely and securely used during orthopedic surgery. Interfascial plane blocks are the latest used ones for analgesia. There are studies in literature indicating that bupivacaine cause myotoxicity. We aimed to examine plasma CPK(creatine phosphokinase) levels to see whether myotoxicity occurs or not after suprainguinal fascial plane block is applied to patients undergoing knee artroplasty surgery.

Completed

Looking for future studies?

Notify Me

Key information

About this study

During 2 months period all elligible patients undergoing knee artoplasty surgery will be included in the study. Different postoperative analgesic modalities will be used according to the anesthesists experience. During routine blood sample tests plasma CPK levels will be tested 3 times of all patients.(preoperative, postoperative 6th hour, postoperative 24th hour) this data will be recorded for 2 months. After this period of time data will be analysed and patients will be grouped according to the analgesic modalities used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA 1-3
  • knee artoplasty patients
  • under spinal anesthesia

Exclusion criteria

  • local anesthetic allergies
  • myopathies
  • coagulopathies
  • Obstructive sleep apne syndrome
  • hearth diseases
  • liver diseases
  • kidney diseases
  • thyroid-parathyriod dieseas
  • hiperlipidemias using Statins(HMG-CoA reductase inhibitors)
  • pregnancy

Treatment and study plan

suprainguinal fascia iliaca block

Other

Suprainguinal fascia iliaca block will be performed after the end of surgery for postoperative analgesia.

Primary outcomes

  1. CPK levels

    Time frame: at postoperative 24th hour

    Change from Baseline serum creatine phosphokinase at 24 hours

Secondary outcomes

  1. Number of patients requesting rescue analgesics

    Time frame: up to 24 hours

    Intravenous administration of meperidine 25 mg as a rescue analgesic is planned for patients who complain of severe pain despite multimodal analgesia.

Sponsors and collaborators

Lead sponsor

Samsun University

Other

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 18, 2022
Registry last updated
Feb 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.